7765-97-1

Basic information

• Product Name: 3-(2-HYDROXY-2-PROPYL)PHENOL
• Synonyms: 3-(2-HYDROXY-2-PROPYL)PHENOL;M-HYDROXYCUMYL ALCOHOL;3-(2-Hydroxypropan-2-yl)phenol
• CAS NO: 7765-97-1
• Molecular Formula: C₉H₁₂O₂
• Molecular Weight: 152.19
• Mol File: 7765-97-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 105-106 °C
• Boiling Point: 288.2°C at 760 mmHg
• Flash Point: 140°C
• Appearance: /
• Density: 1.122g/cm³
• Vapor Pressure: 0.0011mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 9.94±0.10(Predicted)
• CAS DataBase Reference: 3-(2-HYDROXY-2-PROPYL)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-HYDROXY-2-PROPYL)PHENOL(7765-97-1)
• EPA Substance Registry System: 3-(2-HYDROXY-2-PROPYL)PHENOL(7765-97-1)

Safety Data

• Hazardous Substances Data: 7765-97-1(Hazardous Substances Data)

Usage

Uses

3-(2-Hydroxypropan-2-yl)phenol is an intermediate in the preparation of DDAO (D195160).

InChI:InChI=1/C9H12O2/c1-9(2,11)7-4-3-5-8(10)6-7/h3-6,10-11H,1-2H3

Upstream product

• 917-54-4 methyllithium 
• 99-06-9 3-Carboxyphenol 
• 618-45-1 3-isopropylhydroxybenzene 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 676-58-4 methylmagnesium chloride 
• 121-71-1 3-Hydroxyacetophenone 
• 101-38-2 2,6-dichloroquinone-4-chloroimide 
• 64-17-5 ethanol 
• 917-64-6 methyl magnesium iodide 
• 13387-60-5 3-(2-hydroxy-2-propyl)-1-(2-hydroperoxy-2-propyl)benzene 

Downstream Products

• 51985-05-8 acetic acid-(3-isopropenyl-phenyl ester) 
• 63721-03-9 m-Acetoxycumylchlorid 
• 63721-01-7 Diethyl-m-phosphoryloxycumylchlorid 
• 1251827-25-4 2-(3-((R)-2-((1R,3αS,7αR,E)-4-(2-((3R,5R)-3,5-bis(tert-butyldimethylsilyloxy)4-methylenecyclohexylidene)ethylidene)-7αmethyloctahydro-1H-inden-1-yl)propoxy)phenyl)propan-2-ol 
• 46765-25-7 2-(4'-hydroxyphenyl)-2-(3'-hydroxyphenyl)-propane 
• 125185-86-6 3-(2-hydroperoxy-2-propyl)phenol 
• 19102-16-0 (3-isopropenyl-phenoxy)-acetic acid 
• 25108-57-0 3-(1-methylethenyl)anisole 
• 51985-06-9 3-hydroxy-alpha-methylstyrene 
• 118290-03-2 2,6-Dichloro-4-[4-hydroxy-2-(1-hydroxy-1-methyl-ethyl)-phenylamino]-phenol 
• 118290-05-4 1,3-dichloro-7-hydroxy-9,9-dimethyl-9H-acridin-2⁽⁷⁾-one 
• 81194-51-6 4-(3-hydroxyphenyl)-4-methyl-1-pentene 
• 137041-53-3 2,6-Dichloro-4-[4-hydroxy-2-(1-hydroxy-1-methyl-ethyl)-phenylimino]-cyclohexa-2,5-dienone 
• 63720-99-0 Diethyl-m-isopropylenphenylphosphat 

Relevant articles and documents

Method for selectively oxidizing cumene compounds

The invention relates to a method for selectively oxidizing cumene compounds, and the method comprises the following steps: placing cumene compounds shown in a formula (I), an iron porphyrin catalyst,an oxidant and a dispersant into a ball milling tank, sealing the ball milling tank, performing ball milling for 3 to 24 hours at a rotating speed of 100 to 800 rpm at room temperature, stopping ballmilling once every 1 to 3 hours in the ball milling process, discharging gases in the ball milling tank, finishing the reaction, and performing post-treatment on a reaction mixture to obtain product2-phenyl-2-propanol compound shown in a formula (II); according to the invention, the oxidation conversion of the cumene and derivatives thereof is realized through solid-phase ball milling, the reaction mode is novel, the operation is convenient, and the energy consumption is low; the method needs no organic solvent, thus effectively avoiding the use of toxic and harmful organic solvents and being green and environment-friendly; has low peroxide content and high safety factor, and high 2-phenyl-2-propanol and derivative selectivity and meets the social requirements of the current green chemical process, environmental compatibility chemical process and biological compatibility chemical process.

LXR AGONISTS AND USES THEREOF

This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

VITAMIN D RECEPTOR AGONISTS AND USES THEREOF

Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.